News Clinigen buys remaining rights to Novartis cancer drug UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million.
News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering
News Roche’s Tecentriq + Avastin racks up another combination suc... Roche has produced new data showing a combination of Tecentriq and older drug Avastin is more effective than standard therapy for delaying progression in kidney cancer patients.
News NICE says no to Ipsen’s kidney cancer drug NICE has issued draft guidance which rejects Ipsen's Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC).
News NICE recommends Novartis kidney cancer drug Afinitor finally recommended after rejection in 2011.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
